Allergy shots may unlock better asthma control by targeting hidden immune signals

NCT ID NCT07694947

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study looks at how allergy shots (subcutaneous allergen immunotherapy) affect immune markers in adults with allergic asthma. Researchers will measure changes in eosinophil cationic protein and sputum eosinophils over six months, along with asthma symptom scores. The goal is to understand whether these markers can predict who will benefit most from this treatment. Participants are adults with partially controlled allergic asthma who are already candidates for allergy shots.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
allergen immunotherapy extract (subcutaneous injection)
What this could lead to
If successful, this could help doctors predict which asthma patients will benefit most from allergy shots, leading to more personalized treatment.
What could go wrong
This is an early observational study, not a large trial. It may not prove that the treatment works for everyone, and some patients may not respond or may have allergic reactions to the shots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLERGIC ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mohamed AbdElmoniem

    Al Mansurah, 35516, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.